Vaccitech

Vaccitech Team

The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two non-replicating viral vectors which safely mimic viral infection in human cells and elicit high magnitude, durable, targeted CD8+ and CD4+ T cell responses and antibodies to clear foreign pathogens and tumours.

Vaccitech is backed by leading investment institutions, including M&G, Tencent, Gilead Sciences, GV (formerly Google Ventures), Sequoia Capital China, Liontrust (formerly Neptune), Korea Investment Partners and Oxford Sciences Innovation.

Vaccitech: Spin out kick starts with £10m from Oxford Sciences Innovation

The Brilliant but Widely Loathed Scientist Behind the AstraZeneca Vaccine – 20 Nov 2021

Oxford Developed Covid Vaccine, Then Scholars Clashed Over Money – 21 Oct 2021

UK Covid booster not necessary for all, says Oxford jab scientist Sarah Gilbert – 10 Sept 2021

Coronavirus could be with us for many years, says vaccine creator -5 July 2021

Vaccitech chief confident of beating mRNA in cancer treatment 21 June 2021

Team Oxford: The seven celebrated scientists who took on Covid-19 – 11 June 2021

Vaccitech Announces Pricing of Initial Public Offering – 29 April 2021

Biotech behind AstraZeneca vaccine aims to raise $117m at IPO 26 April 2021

Irish scientist heads team behind malaria vaccine hailed as breakthrough – 23 April 2021

AstraZeneca vaccine scientists set for £22m payday in New York float – 7 April 2021

Vaccitech: Oxford vaccine pioneers in line for payout worth millions

AstraZeneca, once touted as a pandemic slayer, faces challenges – 22 March 2021

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results – 17 March 2021

AstraZeneca Company Tied to UK Eugenics Movement – 2 March 2021

Prof Sarah Gilbert: The woman who designed the Oxford vaccine – 23 Nov 2020

Sarah Gilbert

Are you thinking something is not quite right here?